Replimune, a Massachusetts biotech, has won accelerated FDA approval for its advanced melanoma therapy — a reversal that arrives after the agency rejected the drug twice.
According to Endpoints News, the approval came Thursday and caps a stretch that included two rejections, public clashing with the previous FDA leadership, and a closed-door meeting with the White House. Endpoints framed it as the company's "eureka moment."
BioPharma Dive reports the clearance also followed the support of an FDA advisory panel that disputed the arguments made by the agency's own scientists — an unusual public split between outside advisers and internal reviewers. BioPharma Dive identifies the therapy as Tudriqev, developed under the name RP1.
A few things are worth spelling out for non-specialists. "Accelerated approval" is a faster FDA pathway that lets a drug reach patients based on earlier or less definitive evidence than a full approval requires, typically with the expectation that the company keeps studying it. And a rejection from the FDA is not always the end of the road: companies can respond to the agency's concerns and try again, though doing it twice, in public, is rare and expensive.
The sources describe an approval shaped as much by process and politics as by data — advisers overruling staff scientists, a company airing its disagreements publicly, and a meeting at the White House along the way.
Why it matters: for patients with advanced melanoma it means a new treatment option, and for the wider drug industry it is a striking test of whether public pressure and outside advisers can move an FDA decision that had already gone the other way twice.